Top Scoops

Book Reviews | Gordon Campbell | Scoop News | Wellington Scoop | Community Scoop | Search

 

Do You Have Fibromyalgia? Drug Company Hopes So.

Do You Have Fibromyalgia? Drug Company Hopes So.


by Martha Rosenberg


Click to enlarge

Even as new reports surface about fake medical articles Pfizer planted to sell seizure drug Neurontin for unapproved uses from 1995 to 2002, it looks like deja vu all over again.

Pfizer gave nonprofits $2.1 million in grants in 2008 for medical courses about the pain-and-fatigue ailment fibromyalgia for which its Neurontin follow-up pill, Lyrica, just happens to be approved.

Lyrica (pregablin), facetiously called Son of Neurontin at Pfizer, was discovered by Northwestern University chemist Richard Silverman in 1989, earning the university a cool $700 million when it sold royalties in late 2007.

It is funding the $100 million Richard and Barbara Silverman Hall for Molecular Therapeutics & Diagnostics, under construction now, which will employ 245 faculty, staff and research assistants and hopefully lead to other promising molecules.

Like Neurontin (gabapentin), Lyrica (Pregablin) is an antiepilepsy drug (AED) that modulates calcium channels to dampen the excitability of nerve endings and seizure activity. And, like Neurontin which made $3 billion a year from unapproved uses like bipolar disorder, attention deficit disorder and restless legs syndrome, Pfizer has high hopes for its "crossover appeal."

Lyrica was approved in 2006 for partial onset seizures and nerve pain associated with diabetes and shingles. But the FDA's approval of Lyrica as the first drug for fibromyalgia in 2007 is what kicked sales up 37 percent in the third quarter to $465 million.

Fibromyalgia, with no clear cause, blood test, definition or cure "is almost a textbook definition of an unmet medical need," enthused Pfizer VP Ian Read in a conference call to analysts when the drug first launched.

No kidding! Datamonitor predicts the fibro market can be "grown" from $400 million to $2 billion thanks to all the people who don't know they have it yet.

And even before the name Lyrica appeared, Pfizer's initial "unbranded" campaign of public service announcements in conjunction with the National Fibromyalgia Association--are you listening broadcast executives? PSAs?-- that featured people describing their symptoms and hawking the web site www.fibrohope.org moved script big time.

(Think Merck's "unbranded" HPV vaccine Gardasil campaign.)

Despite a temporary Lyrica scare in 2001when Pfizer had to freeze patient trials because mice developed cancerous tumors--luckily the rats didn't--Lyrica was well received by the medical community.

Except they were all on the same team.

"Well tolerated," said Pfizer paid doctors in Arthritis and Rheumatism in 2005.

"Proven efficacy" and "No new adverse events," said Pfizer paid doctors in Drugs of Today in 2005 and 2007.

And, "Durability of effect for relieving FM pain," said Pfizer paid doctors in the journal Pain in 2008.

Actual Lyrica users were less effusive, reporting memory loss, mental confusion, extreme weight gain, hair loss, impaired driving, disorientation, twitching and even two deaths on askapatient.com. And the FDA added suicide warnings to all AEDs in 2008.

Nor is the bad press over for Pfizer. The News Tribune reported Pfizer reps made over 200 visits to Western State Hospital, a mental hospital in Tacoma, Washington, within four years--"That's where our customers are," snapped then company spokesman Bryant Haskins--where 118 prescriptions for Pfizer's controversial drug Geodon were ordered in just one day.

And after paying $430 million in 2004 to settle Neurontin criminal charges, it agreed to pay $2.3 billion just last month for improper marketing of its painkiller, Bextra which was so dangerous it was withdrawn in 2005. Who can say incorrigible?

Few even noticed the repeat offense as Pfizer acquired rival Wyeth at the same time whose Fen Phen and Premarin travail make Pfizer's profile look like Sir Galahad's.

Hopefully, when Pfizer adds social phobia and general anxiety to conditions Lyrica can treat, it will remember to add headache. It will need a lot for itself.

*************

Martha Rosenberg is a columnist/cartoon who writes about public health.

© Scoop Media

 
 
 
Top Scoops Headlines

 

Gordon Campbell: On The Use Of Existing Drugs To Reduce The Effects Of Coronavirus

So now, we’re all getting up to speed with the travel bans, the rigorous handwashing and drying, the social distancing, and the avoidance of public transport wherever possible. Right. At a wider level…so far, the public health system has ... More>>

Gordon Campbell: On Oil Market And Regulation Crusades

Safe to say, Vladimir Putin did not expect the response he has received amidships from the Crown Prince of Saudi Arabia. Earlier, Russia chose to walk away from the OPEC talks in Vienna that were aimed at reaching an agreement on how to reduce world oil production (and protect oil prices) in the light of the fall in demand being caused by the coronavirus. No doubt, Russia and its allies in the US shale industry probably glimpsed an opportunity to undercut OPEC and seize some of its customers. Bad move. In reply, Saudi Arabia has smashed the oil market by hugely ramping up production, signing up customers and drastically cutting the oil price in a fashion designed to knock Russia and other oil suppliers right out of contention. More>>

Gordon Campbell: On 22 Short Takes About Super Tuesday

With obvious apologies to the Simpsons….Here’s my 22 short takes on the 14 Super Tuesday primaries that combined yesterday to produce a common narrative –Bernie Sanders NOT running away with the nomination, Joe Biden coming back from the dead, and the really, really rich guy proving to be really, really bad at politics. In the months ahead, it will be fascinating to see if the real Joe Biden can live up to the idea of Joe Biden that people voted for yesterday – namely, the wise old guy who can save the country from the political extremism of the right and the left... More>>

Gordon Campbell On Shane Jones: A Liability No-One Needs To Bear

New Zealand First has needed a diversion after weeks of bad coverage over its dodgy handling of donations, but it really, really doesn’t need what Shane Jones has chosen to provide. According to Jones, New Zealand has ... More>>

Binoy Kampmark: Strong Man Legacies: Burying Mubarak

Reviled strongmen of one era are often the celebrated ones of others. Citizens otherwise tormented find that replacements are poor, in some cases even crueller, than the original artefact. Such strongmen also serve as ideal alibis for rehabilitation ... More>>

Caitlin Johnstone: Humanity Is Making A Very Important Choice When It Comes To Assange

The propagandists have all gone dead silent on the WikiLeaks founder they previously were smearing with relentless viciousness, because they no longer have an argument. The facts are all in, and yes, it turns out the US government is certainly and undeniably working to exploit legal loopholes to imprison a journalist for exposing its war crimes. That is happening, and there is no justifying it... More>>

Gail Duncan: Reframing Welfare Report

Michael Joseph Savage, the architect of the 1938 Social Security Act, wouldn’t recognise today’s Social Security Act as having anything to do with the kind, cooperative, caring society he envisioned 80 years ago. Instead society in 2020 has been reduced ... More>>


Gordon Campbell: On The Addiction To Chinese Student Fees

Last week, Australian PM Scott Morrison extended its ban on foreign visitors from or passing through from mainland China – including Chinese students - for a third week. New Zealand has dutifully followed suit, with our travel ban ... More>>

Gordon Campbell: On Coronavirus, And The Iowa Debacle

As Bloomberg says, the coronavirus shutdown is creating the world’s biggest work-from-home experiment. On the upside, the mortality rate with the current outbreak is lower than with SARS in 2003, but (for a number of reasons) the economic impact this time ... More>>

Gordon Campbell: On Dodging A Bullet Over The Transport Cost Over-Runs

As New Zealand gears up to begin its $6.8 billion programme of large scale roading projects all around the country, we should be aware of this morning’s sobering headlines from New South Wales, where the cost overruns on major transport projects ... More>>


 
 
 
 
 


 
 
 
  • PublicAddress
  • Pundit
  • Kiwiblog